Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

PTC Therapeutics Q4 2023 Adj EPS $(0.240) Misses $0.500 Estimate, Sales $307.056M Miss $321.294M Estimate

Author: Benzinga Newsdesk | February 29, 2024 05:24pm
PTC Therapeutics (NASDAQ:PTCT) reported quarterly losses of $(0.240) per share which missed the analyst consensus estimate of $0.500 by 148 percent. The company reported quarterly sales of $307.056 million which missed the analyst consensus estimate of $321.294 million by 4.43 percent. This is a 83.41 percent increase over sales of $167.412 million the same period last year.

Posted In: PTCT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist